CLINICAL TRIALS

PET Imaging

Currently, imaging agent pH001, is in the process of clinical translation as novel nuclear imaging marker of diseased tissue acidity.

Clinical trials will be carried out at the Memorial Sloan Kettering Cancer Center in 2019.

Fluorescence-Guided Surgery

Currently, imaging agent pH002, is in the process of clinical translation as a novel marker of blood flow and as an imaging agent for visualization of cancerous lesions in primary tumors and lymph nodes.

Clinical trials will be initiated at the Memorial Sloan Kettering Cancer Center in 2019.